Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
Oct 28, 2025
.png "oral solid dosage forms")
Oral Solid Dosage (OSD) forms – such as tablets and capsules – remain the backbone of modern pharmaceuticals. They are stable, scalable, and preferred by patients for their convenience and ease of administration. As the pharmaceutical landscape evolves, innovation in OSD formulation is vital to improving therapeutic outcomes, optimizing manufacturing, and supporting patient adherence. Today's leading drug formulation development partners are redefining what's possible through advanced science and innovative design.
Modified-release (MR) formulations represent one of the most significant advancements in oral solid dosage forms. By precisely controlling how and when a drug is released into the body, MR technologies help maintain steady plasma levels, enhance efficacy, and reduce the frequency of dosing. Techniques such as hydrophilic matrix systems, osmotic pumps, and polymer coatings are enabling more predictable performance across a diverse range of APIs.
Pharma innovators rely on CDMOs with deep expertise in MR systems to ensure robust design and manufacturability, which are critical to success in drug development and scale-up.
For therapies targeting pediatric, geriatric, or chronic-care populations, patient adherence often hinges on palatability. Taste masking has become a cornerstone of patient-centric OSD formulation. Through techniques such as microencapsulation, coating, and inclusion complexation, formulators can effectively mask bitterness without compromising the bioavailability of the active ingredient.
This focus on sensory experience reflects a broader trend in the industry: placing the patient at the center of drug formulation development. By making medicines more acceptable and easier to take, manufacturers ultimately improve adherence and health outcomes.
As regulatory bodies emphasize the need for safer prescription products, abuse-deterrent formulations (ADFs) have become a vital area of innovation within tablet manufacturing. ADFs are designed to resist physical and chemical manipulation, discouraging misuse while preserving therapeutic efficacy. Using polymer matrices, gelling agents, and aversive compounds, developers can significantly reduce the potential for abuse of controlled substances.
Partnering with a CDMO skilled in ADF technology ensures regulatory compliance and quality without sacrificing performance or scalability.
Among the more innovative oral solid dosage forms, tablet-in-capsule technology offers unique advantages in formulation design and patient convenience. This approach – where one or more mini-tablets are enclosed within a hard gelatin or HPMC capsule – allows for precise control of release profiles, protection of sensitive APIs, and even combination dosing. Its adaptability makes it ideal for both early clinical programs and commercial products, and a smart, efficient option for advancing innovation in oral solids.
As patient needs diversify and regulatory standards become more stringent, OSD innovation will continue to evolve. From modified-release and taste-masking strategies to advanced safety features, the next generation of OSDs will combine scientific precision with patient-centric design.
With expertise spanning early drug development, formulation optimization, and commercial-scale manufacturing, and an unwavering commitment to Patient Centricity, Piramal Pharma Solutions stands ready to support partners in transforming these innovations into real-world therapies.
